ES2585221T3 - Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma - Google Patents
Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma Download PDFInfo
- Publication number
- ES2585221T3 ES2585221T3 ES13172499.9T ES13172499T ES2585221T3 ES 2585221 T3 ES2585221 T3 ES 2585221T3 ES 13172499 T ES13172499 T ES 13172499T ES 2585221 T3 ES2585221 T3 ES 2585221T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- methoxy
- aminocyclopropyl
- methoxyquinolin
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title description 3
- CUDVHEFYRIWYQD-UHFFFAOYSA-N E-3810 free base Chemical compound C=1C=C2C(C(=O)NC)=CC=CC2=CC=1OC(C1=CC=2OC)=CC=NC1=CC=2OCC1(N)CC1 CUDVHEFYRIWYQD-UHFFFAOYSA-N 0.000 title 1
- 239000000543 intermediate Substances 0.000 title 1
- -1 p-toluenesulfonyl Chemical group 0.000 abstract description 7
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000005544 phthalimido group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 abstract 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- VAZQQRNYILEOGE-UHFFFAOYSA-N benzyl n-[1-(hydroxymethyl)cyclopropyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1(CO)CC1 VAZQQRNYILEOGE-UHFFFAOYSA-N 0.000 description 2
- GPPHNOAJKPDJAA-UHFFFAOYSA-N benzyl n-[1-[(4-acetyl-2-methoxy-5-nitrophenoxy)methyl]cyclopropyl]carbamate Chemical compound COC1=CC(C(C)=O)=C([N+]([O-])=O)C=C1OCC1(NC(=O)OCC=2C=CC=CC=2)CC1 GPPHNOAJKPDJAA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- SXLBULLJGDJVCF-UHFFFAOYSA-N benzyl n-[1-[[4-[3-(dimethylamino)prop-2-enoyl]-2-methoxy-5-nitrophenoxy]methyl]cyclopropyl]carbamate Chemical compound COC1=CC(C(=O)C=CN(C)C)=C([N+]([O-])=O)C=C1OCC1(NC(=O)OCC=2C=CC=CC=2)CC1 SXLBULLJGDJVCF-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XEWZVRYIPAYMLS-UHFFFAOYSA-N tert-butyl n-[1-[(4-acetyl-2-methoxy-5-nitrophenoxy)methyl]cyclopropyl]carbamate Chemical compound COC1=CC(C(C)=O)=C([N+]([O-])=O)C=C1OCC1(NC(=O)OC(C)(C)C)CC1 XEWZVRYIPAYMLS-UHFFFAOYSA-N 0.000 description 1
- QGKJNNYJHBEIQQ-UHFFFAOYSA-N tert-butyl n-[1-[(4-acetyl-2-methoxyphenoxy)methyl]cyclopropyl]carbamate Chemical compound COC1=CC(C(C)=O)=CC=C1OCC1(NC(=O)OC(C)(C)C)CC1 QGKJNNYJHBEIQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/44—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de formula (XI) o (XIa):**Fórmula** en donde R' es hidrógeno y R se selecciona de bencilo, acetilo, benzoilo, trifluorometanosulfonilo, bencenosulfonilo, p-toluenosulfonilo, metoxicarbonilo, etoxicarbonilo, tert-butoxicarbonilo, aliloxicarbonilo y benciloxicarbonilo opcionalmente sustituido en el anillo aromático con hasta tres sustituyentes seleccionados de halógeno, ciano y trifluorometilo; o R' es trimetilsililo y R es tert-butoxicarbonilo; o R y R' tomados junto con el átomo de nitrógeno al que están enlazados forman un grupo ftalimido.
Description
5
Un reactor de 10 l equipado con un agitador mecánico se cargó con trifenilfosfina (340.0 g, 1.296 mol) y THF (2 l) y la suspensión se enfrió en un baño helado. La suspensión agitada se añadió después lentamente con DIAD (264 g,
1.296 mol) durante 30 minutos. Después de agitar por 30 min a 0°C, la suspensión agitada se añadió en forma de gotas con una solución de 4-hidroxi-3-metoxiacetofenona (180 g, 1.08 mol) y DIPEA (210 g, 1.62 mol) en THF (1500 10 ml). La suspensión se dejó bajo agitación por 45 min a 0°C, después se añadió en forma de gotas con una solución de 1-benciloxicarbonilamino-1-hidroximetilciclopropano (China Gateway) (240 g, 1.08 mol) en THF (1500 ml). Después de 1h, el análisis LC-MS de una muestra de la mezcla de reacción mostró la desaparición completa de 1benciloxicarbonilamino-1-hidroximetilciclopropano. La mezcla de reacción se evaporó y el producto crudo se recristalizó con EtOH 95% (4000 ml) para dar 1-[(4-acetil-2-metoxifenoxi)metil]-N-benciloxicarbonil-1
15 aminociclopropano (214 g, rendimiento: 53.5%) como un sólido blanco. 1H-RMN (300 MHz, CDCl3): δ: 7.41-7.45 (m, 2 H), 7.26 (s, 5 H), 6.77 (d, 1 H), 5.43 (s, 1H), 5.00 (s, 2 H), 4.04 (s, 2 H), 3.82 (s, 3 H), 2.49 (s, 3H), 0.92 (m, 4 H). LC-MS: M+H+: 370.4
20 Los siguientes compuestos se prepararon análogamente:
1-[(4-Acetil-2-metoxifenoxi)metil)-N-etoxicarbonil-1-aminociclopropano; 1-[(4-Acetil-2-metoxifenoxi)metil]-N-tert-butoxicarbonil-1-aminociclopropano.
25 Ejemplo 2: Preparación de 1-[(4-acetil-2-metoxi-5-nitrofenoxi)metil]-N-benciloxicarbonil-1-aminociclopropano
Una solución de HNO3 (65%, 3 ml) en Ac2O (2 ml) a 0°C se añadió lentamente con una suspensión del compuesto
30 del Ejemplo 1 (1.1 g, 2.9 mmol) en Ac2O (3 ml). Después de agitar a 0°C por 2 h, la mezcla de reacción se vertió en 50 ml de hielo/agua y el precipitado se recuperó por filtración. El sólido amarillo resultante se recristalizó con 95% EtOH (5 ml) para dar 1-[(4-acetil-2-metoxi-5-nitrofenoxi)metil]-N-benciloxicarbonil-1-aminociclopropano (0.69 g, rendimiento: 56%) como un sólido amarillo.1H-RMN (300 MHz, CDC]3): δ: 7.52 (s, 1H), 7.26 (s, 5 H), 6.67 (s, 1 H), 5.36 (s, 1H), 5.02 (s, 2 H), 4.05 (s, 2 H), 3.86
35 (s, 3 H), 2.42 (s, 3 H), 0.94 (m, 4 H). LC-MS: M+H+: 414.41
Los siguientes compuestos se prepararon análogamente:
40 1-[(4-Acetil-2-metoxi-5-nitrofenoxi)metil]-N-etoxicarbonil)-1-aminociclopropano; 1-[(4-Acetil-2-metoxi-5-nitrofenoxi)metil]-N-(tert-butoxicarbonil)-1-aminociclopropano.
Ejemplo 3: Preparación de 1-[(4-(3-dimetilaminopropenoil)-2-metoxi-5-nitrofenoxi) metil]-N-benciloxicarbonil-1aminociclopropano
45
9
Una mezcla del compuesto del Ejemplo 6 (0.24 g, 0.42 mmol) en 2 ml de una solución de 40% HBr en ácido acético se agitó a 30°C por 3h, después se añadió con 10 ml de agua y la mezcla de reacción se extrajo con AcOEt (2 x 10 5 ml). Las fases orgánicas se eliminaron. La solución acuosa se añadió en forma de gotas con una solución de 50% NaOH para alcanzar pH 10. La mezcla se extrajo con DCM (3 x 20 ml) y las fases orgánicas combinadas se secaron y se evaporaron para dar un crudo que contiene 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-N-metil-1naftamida (I) con pureza mayor que >94% por análisis LC-MS. Este crudo se purificó después por cromatografía en una columna de gel de sílice eluyendo con DCM/MeOH 10:1), para proporcionar 6-(7-((1-aminociclopropil)metoxi)-6
10 metoxiquinolin-4-iloxi)-N-metil-1-naftamida (I) con pureza mayor que 98% por análisis LC-MS (140 mg, rendimiento: 76%).1H-RMN (500 MHz, DMSO-d6) δ ppm: 8.47 (d, 2 H), 7.87 (d, 1 H), 7.53 (m, 3 H), 7.51 (m, 1 H), 7.44 (d, 1 H), 7.38 (s, 1 H), 6.50 (d, 1 H), 6.16 (d, 1 H), 5.01 (s, 2 H), 4.05 (s, 2 H), 4.03 (s, 3 H), 3.12 (d, 3 H), 2.09 (m, 2 H), 0.80 (m, 4 H). LC-MS: M+H+: 444.0
15
12
Claims (1)
-
imagen1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2009A000397A IT1393351B1 (it) | 2009-03-16 | 2009-03-16 | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
| ITMI20090397 | 2009-03-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2585221T3 true ES2585221T3 (es) | 2016-10-04 |
Family
ID=41210541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10712320T Active ES2431618T3 (es) | 2009-03-16 | 2010-03-11 | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-N-metil-1-naftamida y productos intermedios sintéticos de la misma |
| ES13172499.9T Active ES2585221T3 (es) | 2009-03-16 | 2010-03-11 | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10712320T Active ES2431618T3 (es) | 2009-03-16 | 2010-03-11 | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-N-metil-1-naftamida y productos intermedios sintéticos de la misma |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8642767B2 (es) |
| EP (3) | EP2641897B1 (es) |
| JP (2) | JP5817079B2 (es) |
| CN (3) | CN104193676B (es) |
| CY (2) | CY1114503T1 (es) |
| DK (2) | DK2408739T3 (es) |
| ES (2) | ES2431618T3 (es) |
| HR (2) | HRP20130978T1 (es) |
| HU (1) | HUE029528T2 (es) |
| IT (1) | IT1393351B1 (es) |
| PL (2) | PL2641897T3 (es) |
| PT (2) | PT2408739E (es) |
| SI (2) | SI2641897T1 (es) |
| SM (1) | SMT201600356B (es) |
| WO (1) | WO2010105761A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1393351B1 (it) | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
| KR102275034B1 (ko) * | 2013-01-18 | 2021-07-12 | 어드밴첸 파마수티컬스, 엘엘씨 | 항-종양제 6-(7-((1-아미노시클로프로필)메톡시)-6-메톡시퀴놀린-4-일옥시)-n-메틸-1-나프타미드 및 그의 결정형을 제조하는 공정 |
| CN105311030B (zh) | 2014-06-06 | 2020-03-24 | 正大天晴药业集团股份有限公司 | 用于抗肿瘤的螺取代化合物 |
| CN105311029A (zh) | 2014-06-06 | 2016-02-10 | 正大天晴药业集团股份有限公司 | 抗肿瘤活性的喹啉衍生物 |
| WO2016010869A2 (en) | 2014-07-14 | 2016-01-21 | Advenchen Pharmaceuticals, LLC | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS |
| AU2015360095B2 (en) | 2014-12-09 | 2020-02-27 | Advenchen Laboratories Nanjing Ltd | Quinoline derivative against non-small cell lung cancer |
| US9751859B2 (en) | 2015-05-04 | 2017-09-05 | Advenchen Pharmaceuticals, LLC | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts |
| CN110128425B (zh) | 2015-07-11 | 2021-09-07 | 南京爱德程医药科技有限公司 | 作为pi3k/mtor抑制剂的芳环或杂环取代的稠合喹啉化合物 |
| KR20180086187A (ko) | 2015-10-05 | 2018-07-30 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료 |
| CN107296811B (zh) | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
| CN109748902B (zh) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | 一种盐酸安罗替尼的制备方法 |
| JP2021517162A (ja) | 2018-03-02 | 2021-07-15 | チア タイ チオギン ファーマスーチカル グループ コーポレイテッド，リミテッド | Ｃ−ｍｅｔキナーゼ阻害剤としての化合物の結晶及びその調製方法及びその使用 |
| JP2021515767A (ja) | 2018-03-07 | 2021-06-24 | バイエル・アクチエンゲゼルシヤフト | Ｅｒｋ５阻害剤の同定及び使用 |
| CN110483392A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 合成n-保护的喹啉-7-基氧基甲基环丙基胺衍生物的方法及合成中间体 |
| CN110483393A (zh) * | 2018-05-14 | 2019-11-22 | 上海海和药物研究开发有限公司 | 德立替尼的晶型 |
| CN109705093A (zh) * | 2018-12-29 | 2019-05-03 | 正大天晴药业集团股份有限公司 | 喹啉衍生物及其制备方法和用途 |
| CN115160221B (zh) * | 2022-07-26 | 2024-10-18 | 恩祺生物科技(上海)有限公司 | 德立替尼晶型化合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT956287E (pt) * | 1996-12-23 | 2003-11-28 | Aventis Pharma Inc | Derivados de 3-aril-2-(1-substituido-4-piperidinil)-1(1-di)oxo-3h-benzo¬disotiazol sua preparacao e sua utilizacao como moduladores da funcao neurotransmissora |
| SK288365B6 (sk) * | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| EP1548008A4 (en) * | 2002-08-23 | 2008-08-06 | Kirin Pharma Kk | COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING |
| EA009994B1 (ru) * | 2003-12-23 | 2008-06-30 | Пфайзер Инк. | Новые хинолиновые производные |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| IT1393351B1 (it) | 2009-03-16 | 2012-04-20 | Eos Ethical Oncology Science Spa In Forma Abbreviata Eos Spa | Procedimento per la preparazione della 6-(7-((1-amminociclopropil)metossi)-6-metossichinolin-4-ilossi)-n-metil-1-naftammide e suoi intermedi di sintesi |
-
2009
- 2009-03-16 IT ITMI2009A000397A patent/IT1393351B1/it active
-
2010
- 2010-03-11 PT PT10712320T patent/PT2408739E/pt unknown
- 2010-03-11 CN CN201410380387.8A patent/CN104193676B/zh not_active Expired - Fee Related
- 2010-03-11 ES ES10712320T patent/ES2431618T3/es active Active
- 2010-03-11 PL PL13172499T patent/PL2641897T3/pl unknown
- 2010-03-11 PL PL10712320T patent/PL2408739T3/pl unknown
- 2010-03-11 JP JP2012500115A patent/JP5817079B2/ja not_active Expired - Fee Related
- 2010-03-11 EP EP13172499.9A patent/EP2641897B1/en active Active
- 2010-03-11 US US13/256,722 patent/US8642767B2/en not_active Expired - Fee Related
- 2010-03-11 WO PCT/EP2010/001519 patent/WO2010105761A1/en not_active Ceased
- 2010-03-11 SI SI201031256A patent/SI2641897T1/sl unknown
- 2010-03-11 EP EP10712320.0A patent/EP2408739B1/en active Active
- 2010-03-11 EP EP16171791.3A patent/EP3103792A1/en not_active Withdrawn
- 2010-03-11 DK DK10712320.0T patent/DK2408739T3/da active
- 2010-03-11 CN CN201080011948.7A patent/CN102356063B/zh not_active Expired - Fee Related
- 2010-03-11 DK DK13172499.9T patent/DK2641897T3/en active
- 2010-03-11 SI SI201030383T patent/SI2408739T1/sl unknown
- 2010-03-11 ES ES13172499.9T patent/ES2585221T3/es active Active
- 2010-03-11 PT PT131724999T patent/PT2641897T/pt unknown
- 2010-03-11 CN CN201610565855.8A patent/CN106187882A/zh active Pending
- 2010-03-11 HR HRP20130978AT patent/HRP20130978T1/hr unknown
- 2010-03-11 HU HUE13172499A patent/HUE029528T2/en unknown
-
2013
- 2013-10-16 CY CY20131100907T patent/CY1114503T1/el unknown
- 2013-12-23 US US14/138,302 patent/US9012645B2/en not_active Expired - Fee Related
-
2015
- 2015-03-18 US US14/661,105 patent/US9340508B2/en not_active Expired - Fee Related
- 2015-05-22 JP JP2015104974A patent/JP6061158B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-29 CY CY20161100749T patent/CY1117871T1/el unknown
- 2016-09-12 HR HRP20161163TT patent/HRP20161163T1/hr unknown
- 2016-10-06 SM SM201600356T patent/SMT201600356B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2585221T3 (es) | Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma | |
| KR101934096B1 (ko) | 이델라리십의 제조방법 | |
| CN114085234B (zh) | 用于制备1,3-苯并间二氧杂环戊烯杂环化合物的方法 | |
| ES2923278T3 (es) | Intermedios útiles para la síntesis de derivados de aminopirimidinas, proceso de preparación del mismo y proceso de preparación de aminopirimidina derivados utilizando los mismos | |
| TW201609694A (zh) | 用於製備３－（３－氯－１ｈ－吡唑－１－基）吡啶的方法（一） | |
| ITMI20102390A1 (it) | Procedimento per la preparazione di linagliptin | |
| JP2013216655A (ja) | ブロナンセリンの改善された調製方法 | |
| CN107814757B (zh) | 一种合成多取代吡咯衍生物的方法 | |
| WO2018205299A1 (zh) | 4，5-二取代-1-氢-吡咯（2，3-f）喹啉-2，7，9-三羧酸酯化合物及应用 | |
| KR102221534B1 (ko) | 치환된 감마 락탐의 합성을 위한 공정 | |
| ES2561879T3 (es) | Derivados de piridilbenzoxazina, composición farmacéutica que comprende los mismos y uso de los mismos | |
| KR102204267B1 (ko) | 대체된 (r)-3-(4-메틸카바모일-3-플루오로페닐아미노)테트라하이드로퓨란-3-엔카르복실산(변이체) 및 이의 에스테르, 제조 방법 및 용도 | |
| MXPA04009414A (es) | Alquilacion estereoselectiva de piperazinas quirales 2-metil-4-protegidas. | |
| CN104592222A (zh) | 抗血小板药物azd6482的制备方法 | |
| KR101069699B1 (ko) | 나프토피란계 광변색 염료의 제조에 사용되는 중간체의 제조방법 | |
| TWI545120B (zh) | ３，４－二氫異喹啉衍生物之製造方法及此等衍生物之製造中間體 | |
| EP3510031B1 (en) | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole | |
| JP2007230941A (ja) | ニトリル化合物又はカルボン酸化合物の製法 | |
| IT202100020591A1 (it) | Preparazione di un intermedio di un agente per il trattamento dell'anemia | |
| IT202100020609A1 (it) | Metodo di preparazione di agente adatto per il trattamento dell'anemia | |
| WO2017005766A1 (en) | A process to make tricycic alcohol intermediates of crth2 antagonists | |
| TW201910336A (zh) | 一種咪唑并異吲哚類衍生物的製備方法 | |
| HK1231871A1 (en) | A process for the preparation of compound and synthetic intermediates thereof | |
| HK1167136B (en) | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-n-methyl-1-naphthamide and synthetic intermediates thereof | |
| JP2017526750A (ja) | スピロ［２．５］オクタン−５，７−ジオンおよびスピロ［３．５］ノナン−６，８−ジオンの調製のための新規なプロセス |